- Home
- DOUG vs ACIU Comparison
DOUG vs ACIU Comparison
Compare DOUG & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DOUG | ACIU |
|---|---|---|
| Founded | 1911 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Building operators | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 210.5M | 213.3M |
| IPO Year | 2021 | 2015 |
Fundamental Metrics
Financial Performance| Metric | DOUG | ACIU |
|---|---|---|
| Price | $2.31 | $3.06 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | ★ 695.6K | 317.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $955,578,000.00 | N/A |
| Revenue This Year | $17.61 | N/A |
| Revenue Next Year | N/A | $495.67 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.48 | $1.43 |
| 52 Week High | $3.20 | $4.00 |
Technical Indicators
Market Signals| Indicator | DOUG | ACIU |
|---|---|---|
| Relative Strength Index (RSI) | 45.82 | 50.66 |
| Support Level | $2.23 | $2.54 |
| Resistance Level | $2.87 | $2.99 |
| Average True Range (ATR) | 0.11 | 0.18 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 75.00 | 78.03 |
Price Performance
Historical ComparisonAbout DOUG Douglas Elliman Inc.
Douglas Elliman Inc is a real estate company. It offers sales, rentals, and new development to mortgages and title insurance, among other services related to real estate. Business is engaged in two operating segments Real Estate Brokerage and Corporate and other. The firm generates income from Commission and other brokerage revenue from existing home sales, Commission and other brokerage income from development marketing, Property management revenue and Title fees. It derives revenue from Real Estate Brokerage segment.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.